ISDA

Deposition Date 2012-01-27

Release Date 2012-04-18

Last Version Date 2024-11-06

Entry Detail

PDB ID:

4DH6

Keywords:

HYDROLASE/HYDROLASE INHIBITOR

Title:

Structure of Bace-1 (Beta-Secretase) in Complex with (2R)-N-((2S,3R)-1-(benzo[d][1,3]dioxol-5-yl)-3-hydroxy-4-((S)-6'-neopentyl-3',4'-dihydrospiro[cyclobutane-1,2'-pyrano[2,3-b]pyridine]-4'-ylamino)butan-2-yl)-2-methoxypropanamide

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.50 Å

R-Value Free:

0.27

R-Value Work:

0.22

R-Value Observed:

0.23

Space Group:

P 61 2 2

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Beta-secretase 1
Gene (Uniprot):BACE1
Mutagens:R-5K, R-4K
Chain IDs:A
Chain Length:411
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P56817 Pfam ID:PF00026 EC:3.4.23.46

Ligand Molecules

0KN

GOL

IOD

Primary Citation

Design and preparation of a potent series of hydroxyethylamine containing beta-secretase inhibitors that demonstrate robust reduction of central beta-amyloid.

Weiss, M.M, Williamson, T, Babu-Khan, S, Bartberger, M.D, Brown, J, Chen, K, Cheng, Y, Citron, M, Croghan, M.D, Dineen, T.A, Esmay, J, Graceffa, R.F, Harried, S.S, Hickman, D, Hitchcock, S.A, Horne, D.B, Huang, H, Imbeah-Ampiah, R, Judd, T, Kaller, M.R, Kreiman, C.R, La, D.S, Li, V, Lopez, P, Louie, S, Monenschein, H, Nguyen, T.T, Pennington, L.D, Rattan, C, San Miguel, T, Sickmier, E.A, Wahl, R.C, Wen, P.H, Wood, S, Xue, Q, Yang, B.H, Patel, V.F, Zhong, W.Show

J.Med.Chem. 55 9009 9024 (2012)

PMID: 22468639 DOI: 10.1021/jm300119p

Abstact

A series of potent hydroxyethyl amine (HEA) derived inhibitors of β-site APP cleaving enzyme (BACE1) was optimized to address suboptimal pharmacokinetics and poor CNS partitioning. This work identified a series of benzodioxolane analogues that possessed improved metabolic stability and increased oral bioavailability. Subsequent efforts focused on improving CNS exposure by limiting susceptibility to Pgp-mediated efflux and identified an inhibitor which demonstrated robust and sustained reduction of CNS β-amyloid (Aβ) in Sprague-Dawley rats following oral administration.

Legend

Protein

Chemical

Disease

Primary Citation of related structures